Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntington’s disease
Abstract Currently, there are no therapies available to modify the disease progression of Huntington’s disease (HD). Recent clinical trial failures of antisense oligonucleotide candidates in HD have demonstrated the need for new therapeutic approaches. Here, we developed a novel in-silico fragment s...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-11-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-21900-2 |